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Microbes have ruled the world 
for approximately 4 billion years. 
But the future actually depends 
on their dominance, some would 
argue. Why? Because microbes, 
as well as mammalian cells, can be 
engineered into producing high-
value chemicals and medicine. 
Therefore, scientists at The Novo 
Nordisk Foundation Center for 
Biosustainability are hard at work 
developing cell factories to benefit 
us all.
Plastic bags, toys, cancer drugs, fuel, 
and food ingredients are just some of a 
huge range of products that are manu-
factured from chemical materials based 
on oil or extracted from plants. This way 
of manufacturing either depletes natural 
resources or takes up big areas of farm-
land. Furthermore, use of fossil fuels 
contributes to increased carbon dioxide 
emissions. Using cheap biomass, for 
instance municipal waste or plant stems, 
would create a sustainable carbon cycle.
But it is still a challenge to synthesize 
very complex compounds chemically 
from cheap biomass. Instead of building 
enormous factories for chemical syn-
thesis, researchers have started looking 
towards the smallest factories known, 
namely cells.
When the Novo Nordisk Founda-
tion Center for Biosustainability was 
established six years ago based on a 
generous grant from the Novo Nordisk 
Foundation, the vision was to build cell 
factories to produce new or existing 
compounds for the pharmaceutical in-
dustry as well as fine chemicals to lessen 
the environmental impact of our modern 
living. Today, we have already taken 
huge steps towards fulfilling this vision.
Hence, a primary aim of the Center is 
to lead the transformation from a petro-
chemical industry to a more sustainable 
bio-based industry in which chemicals 
and drugs are produced bio-technologi-
cally using cell factories.
Big effort to put the research into 
use
The Novo Nordisk Foundation Center 
for Biosustainability is organizationally a 
department at the Technical University 
of Denmark (DTU), and its organization 
is designed to operate at the interface 
of basic and translational research. 
Currently, the Center has nine sections 
situated in Denmark, USA and Sweden, 
which conduct prominent academic 
research. The focus of the sections is on 
cell factory design using state-of-the-art 
bio-analytics, molecular biology, ge-
nome-scale computational models and 
high-throughput screening methods. 
Furthermore, research groups and so-
called core units at the Center focus on 
translating the basic research and matur-
ing it for industrial implementation.
The results are evident
By now, researchers at the Center have 
already taken big leaps in many areas. 
For instance, they have managed to 
Figure 1. Novo Nordisk Foundation Center for Biosustainability. In 2016, the Center 
moved into a new modern building at the DTU’s main campus in Kgs. Lyngby, 12 km north 
of Copenhagen. The Center is collaborating with biotechnology companies in Denmark and 
elsewhere and with the chemical industry to promote knowledge exchange and the appli-
cation of the Center’s results. Photo credit: DTU.
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build E. coli bacteria that produce large 
quantities of the amino acid serine, 
which is otherwise known to be toxic 
to this bacterium. But using advanced 
robotics and so-called adapted labo-
ratory evolution, the researchers first 
trained the bacteria into tolerating high 
concentrations of serine and then engi-
neered the bacteria into producing large 
amounts of this particular amino acid 
[1]. Serine is very interesting commer-
cially, because it is used in makeup, lo-
tions, tube feeding formula, and various 
nutraceuticals. Also, it can be turned 
into a variety of chemicals used in 
plastics and detergents. Other achieve-
ments are engineering of S. cerevisiae 
(baker’s yeast) into producing cocoa 
butter lipids [2], anti-malarial medicine 
[3], and haemoglobin [4] – the oxygen 
carrier of red blood cells.
In terms of commercializing, the 
potential of chemicals produced in cell 
factories is enormous. The turnover of 
the chemical industry is about 3.8 trillion 
Euro per year, or about 5% of the world’s 
GDP. This is roughly evenly divided be-
tween commodity industrial chemicals 
and specialty fine chemicals. Many of 
these chemical compounds can now be 
made biologically by engineering cellu-
lar metabolism and designing microbial 
cell factories.
Using mammalian cells for 
producing proteins
Even though yeast and E.coli can 
achieve many of the researchers’ goals, 
these cells often fall short when it comes 
to producing protein-based drugs. The 
reason being that therapeutic proteins, 
i.e. cancer drugs, blood proteins, en-
zymes for metabolic diseases, vaccines 
and different human hormones have to 
resemble human proteins very closely in 
order not to give an immune response in 
the patient.
The cellular “machinery” for deco-
rating proteins in yeast and bacteria is 
very different from that of human cells. 
Mammalian cells, on the other hand, 
are a perfect fit for this purpose. The 
Center’s focus is on CHO (Chinese 
hamster ovary) cell lines, and the goal 
is to develop robust cell factories that 
efficiently produce therapeutic proteins 
with tailored properties.
CHO cells already produce around 
70% of all protein-based bio-pharma-
ceuticals on the market [5]. In 2009, the 
turnover of the pharmaceutical industry 
was 460 billion Euro per year, with ther-
apeutic proteins accounting for about 
76.5 billion Euro, making this area the 
fastest growing segment of the industry.
Optimization of cell factories is 
crucial
Today’s CHO cell factories can only pro-
duce fairly low amounts of these impor-
tant pharmaceuticals; about 5-10 grams 
of active compound per liter, which 
makes the drugs quite expensive.
Therefore, a big focus area is opti-
mization and upscaling, both when it 
comes to mammalian and microbial cell 
factories. Optimizing cell factories will 
benefit patients, consumers, and the 
environment. Also, we are working on 
discovering and producing new drugs 
and chemicals, that are not on the mar-
ket today, and ready them for commer-
cialization. This will potentially benefit 
industries, attract investors and prepare 
the ground for start-ups and spin-outs 
and hence contribute to a flourishing 
biotech industry.
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Figure 2. Laboratory in the Center for Biosustainability. The interior of the new modern 
building with its high-tech laboratories and spacious offices, attracts highly skilled research-
ers from all over the world and fosters an innovative spirit. The Center is also very inter-
ested in turning future researchers into leaders and pioneers within sustainable industry. 
The Center is therefore educating young scientists within the field and currently has about 
50 PhD students enrolled. Photo credit: Stamers Kontor.
